BioXcel defers $9M payment to Aug 31, cuts liquidity covenant to $6.25M

BioXcel Therapeutics, Inc.

Deferred $9,016,914.47 principal+interest due June 30 to Aug 31, 2026.
Minimum liquidity covenant reduced from $7.5M to $6.25M.
Must enter definitive agreements for acceptable transaction by Aug 10, 2026.
Prohibited from modifying compensation arrangements through Aug 31, 2026.
Oaktree lenders agreed to these amendments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.